CB-86 |
| Catalog No.GC18695 |
CB-86 is a resorcinol-anandamide hybrid compound that acts as a partial agonist for the central cannabinoid (CB1) receptor and a neutral antagonist for the peripheral cannabinoid (CB2) receptor with Ki values of 5.6 and 7.9 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1150586-64-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CB-86 is a resorcinol-anandamide hybrid compound that acts as a partial agonist for the central cannabinoid (CB1) receptor and a neutral antagonist for the peripheral cannabinoid (CB2) receptor with Ki values of 5.6 and 7.9 nM, respectively. Its demonstrated potency is similar to that of WIN 55,212-2 (Ki = 21 and 2.1 nM for CB1 and CB2, respectively). CB-86 (1 mg/kg) exhibits antinociceptive effects in mice treated with formalin.
Review for CB-86
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
Review for CB-86
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *